Table 4.
Univariate and multivariate analysis of variable factors for overall survival and recurrence-free survival
| |
|
Overall survival |
Recurrence-free survival |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
||||||||
| Variable | No. of patients | Median months (95% CI) | 5-years, % (95% CI) | p-value | p-value | HR | HR 95% CI | Median months (95% CI) | 5-years % (95% CI) | p-value | p-palue | HR | HR 95% CI |
| Age |
|
|
|
0.8381 |
|
|
|
|
|
0.4263 |
|
|
|
| ≤ 60 years |
16 |
19 (14–37) |
8.3 (0.6-30.2) |
|
|
|
|
8 (5–13) |
13.3 (2.2-34.6) |
|
|
|
|
| > 60 years |
72 |
25 (18–31) |
12.4 (5.8-21.5) |
|
|
|
|
8 (6–10) |
5.6 (1.8-12.5) |
|
|
|
|
| Gender |
|
|
|
0.6264 |
|
|
|
|
|
0.8117 |
|
|
|
| Male |
57 |
23 (17–30) |
10.5 (3.9-28.4) |
|
|
|
|
7 (5–11) |
7.1 (2.3-15.8) |
|
|
|
|
| Female |
31 |
24 (15–37) |
14.3 (4.6-29.3) |
|
|
|
|
9 (6–11) |
6.5 (1.1-18.6) |
|
|
|
|
| Primary tumor |
|
|
|
0.1872 |
|
|
|
|
|
0.7773 |
|
|
|
| Colon |
69 |
19 (16–27) |
8.6 (3.3-17.2) |
|
|
|
|
8 (6–10) |
5.9 (1.9-13.2) |
|
|
|
|
| Rectum |
19 |
33 (23–58) |
23.7 (7.2-45.5) |
|
|
|
|
7 (4–13) |
10.5 (1.8-28.4) |
|
|
|
|
| Node status |
|
|
|
0.8512 |
|
|
|
|
|
0.4566 |
|
|
|
| Positive |
65 |
25 (19–32) |
11.4 (5.0-2.8) |
|
|
|
|
8 (6–10) |
6.2 (2.0-13.8) |
|
|
|
|
| Negative |
23 |
18 (14–33) |
13.0 (2.6-32.3) |
|
|
|
|
10 (5–13) |
9.1 (1.6-25.1) |
|
|
|
|
| CLM |
|
|
|
0.9861 |
|
|
|
|
|
0.2889 |
|
|
|
| Synchronous |
22 |
20 (18–35) |
9.1 (1.6-25.1) |
|
|
|
|
10 (7–13) |
4.5 (0.3-18.9) |
|
|
|
|
| Metachronous |
66 |
26 (16–32) |
12.4 (5.4-22.4) |
|
|
|
|
7 (5–10) |
7.7 (2.8-15.8) |
|
|
|
|
| CEA level before RFA |
|
|
|
0.0189 |
0.0325 |
|
|
|
|
0.0062 |
0.0442 |
|
|
| ≤ 100 ng/ml |
51 |
29 (19–37) |
15.3 (6.7-27.0) |
|
|
|
|
10 (8–12) |
9.8 (3.6-19.7) |
|
|
|
|
| > 100 ng/ml |
37 |
15 (11–25) |
6.9 (1.4-19.1) |
|
|
1.672 |
1.044-2.678 |
6 (4–7) |
2.8 (0.2-12.4) |
|
|
1.637 |
1.013-2.647 |
| Maximum size of CLM |
|
|
|
0.0001 |
0.0939 |
|
|
|
|
<0.0001 |
0.0771 |
|
|
| ≤ 3 cm |
61 |
30 (23–36) |
15.3 (7.2-26.1) |
|
|
|
|
10 (8–11) |
9.8 (4.0-18.8) |
|
|
|
|
| 3-5 cm |
27 |
12 (10–19) |
3.8 (0.3-16.4) |
|
|
1.548 |
0.928-2.581 |
5 (4–6) |
0 |
|
|
1.600 |
0.950-2.694 |
| Number of CLM |
|
|
|
<0.0001 |
<0.0001 |
|
|
|
|
0.0093 |
0.0389 |
|
|
| 1-3 |
67 |
27 (21–36) |
15.6 (7.8; 25.9) |
|
|
|
|
8 (7–11) |
9.0 (3.6-17.2) |
|
|
|
|
| 4-5 |
21 |
12 (10–18) |
0 |
|
|
3.128 |
1.771-5.526 |
5 (4–10) |
0 |
|
|
1.771 |
1.029-3.048 |
| Response to systemic therapy before RFA |
|
|
|
<0.0001 |
0.0005 |
|
|
|
|
<0.0001 |
<0.0001 |
|
|
| Partial remission |
49 |
37 (32–48) |
21.6 (10.9-34.7) |
|
|
|
|
11 (10–13) |
12.5 (5.1-23.4) |
|
|
|
|
| Stable disease |
13 |
19 (15–25) |
0 |
|
|
|
|
8 (6–10) |
0 |
|
|
|
|
| Progressive disease | 26 | 10 (9–11) | 0 | 5.456 | 2.289-13.005 | 4 () | 0 | 6.458 | 2.644-15.78 | ||||
Abbreviations: 95% CI, 95% confidence interval; CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; HR, Hazard ratio; RFA, radiofrequency ablation.